433 Shares in Eli Lilly and Company (NYSE:LLY) Bought by Accredited Wealth Management LLC

Accredited Wealth Management LLC bought a new position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 433 shares of the company's stock, valued at approximately $334,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Principal Financial Group Inc. lifted its stake in Eli Lilly and Company by 5.3% in the 3rd quarter. Principal Financial Group Inc. now owns 1,208,545 shares of the company's stock valued at $1,070,698,000 after acquiring an additional 60,306 shares in the last quarter. Versant Capital Management Inc raised its holdings in shares of Eli Lilly and Company by 19.2% in the fourth quarter. Versant Capital Management Inc now owns 1,167 shares of the company's stock valued at $901,000 after purchasing an additional 188 shares during the last quarter. Modus Advisors LLC lifted its position in shares of Eli Lilly and Company by 67.0% in the fourth quarter. Modus Advisors LLC now owns 800 shares of the company's stock worth $618,000 after purchasing an additional 321 shares in the last quarter. Everence Capital Management Inc. lifted its position in shares of Eli Lilly and Company by 3.2% in the fourth quarter. Everence Capital Management Inc. now owns 22,340 shares of the company's stock worth $17,246,000 after purchasing an additional 690 shares in the last quarter. Finally, Nordea Investment Management AB grew its position in Eli Lilly and Company by 13.7% in the fourth quarter. Nordea Investment Management AB now owns 1,154,350 shares of the company's stock valued at $887,014,000 after purchasing an additional 138,835 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company's stock.

Analysts Set New Price Targets

Several brokerages have commented on LLY. Leerink Partners set a $950.00 price target on shares of Eli Lilly and Company in a research report on Friday, January 17th. Wells Fargo & Company restated an "overweight" rating on shares of Eli Lilly and Company in a research note on Thursday. UBS Group lowered their price target on Eli Lilly and Company from $1,100.00 to $1,050.00 and set a "buy" rating on the stock in a research report on Friday. The Goldman Sachs Group raised Eli Lilly and Company from a "neutral" rating to a "buy" rating and cut their price objective for the company from $892.00 to $888.00 in a report on Tuesday, April 8th. Finally, Truist Financial boosted their target price on shares of Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the stock a "buy" rating in a report on Monday, February 3rd. One research analyst has rated the stock with a sell rating, two have issued a hold rating and nineteen have assigned a buy rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $1,002.80.

Eli Lilly and Company Stock Performance

NYSE:LLY opened at $825.10 on Friday. The company has a current ratio of 1.15, a quick ratio of 0.97 and a debt-to-equity ratio of 2.00. The stock has a 50 day simple moving average of $825.36 and a 200 day simple moving average of $816.37. Eli Lilly and Company has a 1-year low of $677.09 and a 1-year high of $972.53. The stock has a market cap of $782.34 billion, a P/E ratio of 70.46, a PEG ratio of 1.40 and a beta of 0.51.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its earnings results on Thursday, May 1st. The company reported $3.34 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $4.64 by ($1.30). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. The business had revenue of $12.73 billion during the quarter, compared to the consensus estimate of $12.77 billion. During the same period in the previous year, the firm posted $2.58 EPS. The company's revenue was up 45.2% compared to the same quarter last year. Research analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Insiders Place Their Bets

In related news, CAO Donald A. Zakrowski sold 1,000 shares of the business's stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total value of $818,240.00. Following the completion of the sale, the chief accounting officer now directly owns 5,840 shares in the company, valued at approximately $4,778,521.60. The trade was a 14.62 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 0.13% of the company's stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.